Standard of Care: Personalizing Your Treatment Plan
At a Glance
Treatment for differentiated thyroid cancer is highly personalized based on your specific risk of recurrence. Standard care typically involves surgery, such as a lobectomy or total thyroidectomy, often followed by radioactive iodine therapy and TSH suppression to prevent cancer growth.
Treatment for differentiated thyroid cancer is no longer a “one-size-fits-all” approach. Current guidelines emphasize personalizing care based on your specific risk of recurrence [1].
Surgical Options: Lobectomy vs. Total Thyroidectomy
The first step in treatment is almost always surgery. There are two primary types:
- Thyroid Lobectomy: Removal of only half of the thyroid. This is now a standard option for low-risk tumors (e.g., less than 4 cm) that are confined to the thyroid [2][3]. It has a lower risk of side effects like permanent low calcium (hypoparathyroidism).
- Total Thyroidectomy: Removal of the entire gland. This is usually recommended for larger tumors, high-risk variants, or if the cancer has spread to lymph nodes or other organs [3].
Radioactive Iodine (RAI) Therapy
RAI is a treatment where you swallow a small amount of radioactive iodine to target and destroy thyroid cells. It is not always necessary for low-risk patients [1]. It is used for three different reasons:
- Remnant Ablation: To destroy any small amount of healthy thyroid tissue left over after surgery.
- Adjuvant Therapy: To target any microscopic cancer cells that might remain, reducing the risk of recurrence.
- Treatment: To treat cancer that has spread to other parts of the body (metastasis) [4].
Important Realities of RAI:
While it is an effective tool, RAI requires careful preparation and carries side effects.
- Preparation: You will need to be in a “hypothyroid” state to absorb the iodine. This is achieved by either temporarily stopping your thyroid hormone medication or by receiving Thyrogen injections [4].
- Isolation Requirements: Because you will be temporarily radioactive, you must strictly isolate yourself for several days. This means sleeping in a separate room, avoiding hugs, using a separate bathroom, and staying away from pregnant women, young children, and pets.
- Side Effects: While generally well-tolerated, common side effects include salivary gland damage (resulting in persistent dry mouth), altered taste, and sometimes tear duct issues.
TSH Suppression: Balancing Benefits and Risks
After surgery, you will take thyroid hormone replacement (levothyroxine). In many cases, doctors prescribe a dose slightly higher than what your body needs to “suppress” your Thyroid-Stimulating Hormone (TSH) [5]. Lowering TSH helps prevent cancer cells from growing. However, keeping TSH too low for too long can cause side effects:
- Heart Issues: Increased risk of atrial fibrillation (irregular heartbeat) and cardiovascular morbidity [6].
- Bone Health: Decreased bone mineral density and a higher risk of fractures, especially in older adults [6].
Because of these risks, doctors now “de-escalate” or relax TSH targets as you remain cancer-free [7][8].
Advanced Options: Targeted Therapy
For a small number of patients, the cancer may stop responding to RAI (radioiodine-refractory). If this happens and the disease is progressive, doctors investigate targeted therapies (such as kinase inhibitors) [9][10]. These medications work by blocking the specific pathways the cancer uses to grow and create new blood vessels [11].
Common questions in this guide
Am I a candidate for a thyroid lobectomy instead of a total thyroidectomy?
Why might I need radioactive iodine (RAI) therapy?
How do I prepare for radioactive iodine treatment?
What are the isolation rules after radioactive iodine treatment?
What are the risks of long-term TSH suppression?
What happens if my cancer stops responding to radioactive iodine?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my ATA risk category, am I a candidate for a thyroid lobectomy instead of a total thyroidectomy?
- 2.What is the specific goal of my radioactive iodine treatment—is it 'remnant ablation,' 'adjuvant therapy,' or 'treatment' for known spread?
- 3.What is my long-term 'target TSH' level? If I am low-risk, can we avoid aggressive suppression to protect my heart and bones?
- 4.At what point would we consider the cancer 'radioiodine-refractory,' and what are the next steps for targeted therapy if that happens?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (11)
- 1
Dynamic risk assessment in patients with differentiated thyroid cancer.
Pitoia F, Jerkovich F
Endocrine-related cancer 2019; (26(10)):R553-R566.
PMID: 31394499 - 2
Neoadjuvant tyrosine kinase inhibitor therapy for locally advanced, well-differentiated thyroid cancer.
Bock R, Arman S, Ardila Pardo GL, et al.
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2026; doi:10.1016/j.surge.2026.05.001.
PMID: 42303504 - 3
Radioiodine therapy in the different stages of differentiated thyroid cancer.
Valerio L, Maino F, Castagna MG, Pacini F
Best practice & research. Clinical endocrinology & metabolism 2023; (37(1)):101703 doi:10.1016/j.beem.2022.101703.
PMID: 36151009 - 4
Strategies for Radioiodine Treatment: What's New.
Sparano C, Moog S, Hadoux J, et al.
Cancers 2022; (14(15)) doi:10.3390/cancers14153800.
PMID: 35954463 - 5
Thyroid Hormone Suppression Therapy.
Biondi B, Cooper DS
Endocrinology and metabolism clinics of North America 2019; (48(1)):227-237 doi:10.1016/j.ecl.2018.10.008.
PMID: 30717904 - 6
Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms.
Pishdad R, Ahmadi S
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):401-405 doi:10.1016/j.eprac.2025.12.002.
PMID: 41407103 - 7
A Qualitative Study of Clinician Barriers and Facilitators to De-escalation of Thyroid Stimulating Hormone Suppression in Thyroid Cancer Survivors.
Francis-Levin N, Tan CY, Gay BL, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(3)):392-400 doi:10.1016/j.eprac.2025.12.009.
PMID: 41419177 - 8
Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C, Wémeau JL
Annales d'endocrinologie 2015; (76(1 Suppl 1)):1S47-52.
PMID: 26826483 - 9
Molecular Perspectives in Radioactive Iodine Theranostics: Current Redifferentiation Protocols for Mis-Differentiated Thyroid Cancer.
Gulec SA, Benites C, Cabanillas ME
Journal of clinical medicine 2024; (13(13)) doi:10.3390/jcm13133645.
PMID: 38999211 - 10
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS, Cabanillas ME, Cohen EE, et al.
The Lancet. Oncology 2016; (17(9)):1272-82.
PMID: 27460442 - 11
Cell-state transitions and microenvironmental remodeling in thyroid cancer progression revealed by single-cell and spatial transcriptomics.
Wang X, Tao D, Xu J, et al.
Frontiers in immunology 2026; (17()):1904196 doi:10.3389/fimmu.2026.1904196.
PMID: 42488635
This page is for informational purposes only and does not replace professional medical advice. Always consult your endocrinologist or oncologist regarding your specific thyroid cancer treatment plan.
Get notified when new evidence is published on thyroid gland papillary and follicular carcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.